NYSE:BSX

Track all markets on TradingView - Prices are not updated in real time
Boston Scientific Stock Edges Higher After Solid Q2 Results Despite Cautious Full-Year Outlook

Boston Scientific (NYSE: BSX) shares were up 1.3% on Wednesday following the company's second-quarter earnings report, as investors balanced another quarter of strong execution against a more moderate growth outlook for the second half of 2026.

The medical device maker reported second-quarter revenue of $5.44 billion, up 7.5% year over year, while organic sales increased 7.0%, reaching the high end of its guidance range. GAAP EPS rose to $0.61 from $0.53 a year earlier, while adjusted EPS climbed to $0.86, exceeding management's guidance of $0.82 to $0.84.

Performance remained broad-based across the portfolio. Cardiovascular revenue increased 8.3%, supported by continued demand for electrophysiology and structural heart products, while the MedSurg segment grew 5.9%. International markets also remained a key growth driver, with Asia-Pacific revenue rising 11.2% and Latin America and Canada posting 22.4% growth.

Boston Scientific continued to invest aggressively in future growth, including a $1.5 billion investment in MiRus to expand its structural heart platform. The company also announced positive clinical data for several cardiovascular technologies and continued advancing its next-generation electrophysiology portfolio.

Management updated its full-year 2026 guidance, forecasting reported revenue growth of 5.5% to 6.5%, organic revenue growth of 5% to 6%, and adjusted EPS of $3.28 to $3.32. Third-quarter guidance calls for reported and organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82.

The positive share price reaction suggests investors focused on Boston Scientific's continued ability to outperform expectations and execute across its core businesses. While management expects growth to moderate from the exceptional pace seen in recent years, strong profitability, continued innovation, and leadership in high-growth cardiovascular markets continue to support confidence in the company's long-term outlook.
💬
Author
The Investor 07-29-26
Boston Scientific Reports Strong Q2 2025 Results; Raises Guidance

Boston Scientific posted Q2 2025 net sales of $5.06 billion, a 22.8% year-over-year increase, surpassing guidance. GAAP net income rose to $797 million ($0.53/share) from $324 million a year ago, with adjusted EPS at $0.75, also exceeding expectations.

Highlights:
• Cardiovascular segment drove growth with 23.2% organic increase.
• U.S. sales surged 30.7%, while APAC rose 18%.
• Key approvals included FDA expansion for FARAPULSE™ and CE mark for WATCHMAN FLX™ Pro.
• Company completed acquisitions of Intera Oncology and SoniVie Ltd. to enhance its oncology and hypertension portfolios.

CEO Mike Mahoney credited the global team for strong performance and affirmed long-term growth momentum.
💬
Author
The Investor 07-24-25
Boston Scientific Discontinues ACURATE Valve Systems Amid Regulatory Hurdles

Boston Scientific Corporation announced it will cease global sales of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems and withdraw efforts to obtain FDA approval in the U.S. and other markets. The decision follows discussions with regulators that introduced higher clinical and regulatory requirements, making continued investment in the product line prohibitively costly.

Despite this move, the company expects to meet its Q2 and full-year 2025 sales and adjusted EPS guidance, as issued in April. However, it is not reaffirming its GAAP EPS guidance at this time and will provide further updates in its Q2 earnings call.

The announcement includes forward-looking statements and cautions investors that actual outcomes may vary due to market, operational, regulatory, or geopolitical factors.
💬
Author
The Investor 05-29-25

3 Tariff-Resistant US Healthcare Stocks to Consider Adding to Your Portfolio - The Smart Investor

Here are three healthcare stocks that could prove resilient against Trump’s raft of tariffs.

(thesmartinvestor.com.sg)
💬
Author
European Investor 05-20-25
Boston Scientific has entered into an agreement to acquire SoniVie Ltd., a medical device company that developed the TIVUS Intravascular Ultrasound System. This investigational technology is designed to treat hypertension by denervating nerves surrounding blood vessels, specifically through renal artery denervation. The acquisition expands Boston Scientific’s interventional cardiology portfolio with an ultrasound-based alternative to existing renal denervation therapies.

Hypertension is a leading risk factor for cardiovascular disease, and existing treatments, including medications and lifestyle changes, are often insufficient. The TIVUS system uses ultrasound energy to penetrate tissue more deeply than radiofrequency-based methods, potentially enabling faster procedures with effective nerve ablation.

Boston Scientific currently holds a 10% equity stake in SoniVie. The acquisition involves an upfront payment of approximately $360 million for the remaining 90%, with up to $180 million in additional payments contingent on regulatory milestones. The transaction is expected to close in the first half of 2025. The company anticipates a slight dilutive effect on adjusted earnings in 2025, offset by internal cost efficiencies.

The TIVUS system remains an investigational device and is not yet approved for commercial use. Boston Scientific continues to expand its portfolio of innovative cardiovascular treatments through strategic acquisitions.
💬
Author
Global Finance News 03-03-25
Boston Scientific Corporation has announced the completion of a €1.5 billion public offering of senior notes through its wholly owned finance subsidiary, American Medical Systems Europe B.V. The company had previously announced the pricing of these senior notes on February 21, 2025.

Additionally, Boston Scientific recently reported strong financial results for the fourth quarter and full year 2024, with CEO Mike Mahoney describing it as "one of the best years in the history of the company." The company continues to expand its cardiovascular portfolio, with acquisitions such as Bolt Medical, Inc., and Intera Oncology, Inc., aimed at strengthening its interventional cardiology and oncology offerings.

Boston Scientific will also participate in TD Cowen’s 45th Annual Health Care Conference in March 2025.
💬
Author
Global Finance News 02-27-25
Boston Scientific Corporation has announced the pricing of €1.5 billion in senior notes through its wholly owned finance subsidiary, American Medical Systems Europe B.V. The issuance includes €850 million of 3.000% notes due 2031 and €650 million of 3.250% notes due 2034. The offering is expected to close on February 26, 2025, subject to customary conditions. The proceeds, combined with cash on hand, will be used to repay AMS Europe's 0.750% senior notes due March 8, 2025, and for general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions.
💬
Author
WS Investor 02-22-25
Boston Scientific Corporation reported strong financial results for both the fourth quarter and full year of 2024. The company posted net sales of $4.561 billion for the fourth quarter, reflecting a 22.4% increase on a reported basis and a 19.5% rise on an organic basis, surpassing its guidance range. For the full year, net sales totaled $16.747 billion, marking a 17.6% increase compared to the previous year. The company also saw a rise in net income, with GAAP net income for the fourth quarter reaching $566 million, or $0.38 per share, up from $504 million or $0.34 per share in 2023. Adjusted EPS for the quarter was $0.70, higher than the previous year's $0.55.

The growth was driven by significant performance in the Cardiovascular segment, which saw a 28.8% increase in reported sales, and strong results from the United States, which contributed a 30.7% increase in reported sales. Boston Scientific also highlighted several key developments, including the approval of the FARAPULSE Pulsed Field Ablation System, positive clinical trial results for the WATCHMAN FLX Left Atrial Appendage Closure Device, and multiple strategic acquisitions. The company acquired Axonics, Inc. and Cortex, Inc., expanding its product offerings, while also announcing agreements to acquire Bolt Medical and Intera Oncology, further solidifying its position in the medical device industry.
💬
Author
WS News 02-05-25